Anti-PD-1/PD-L1 therapy for infectious diseases: learning from the cancer paradigm | Zendy

Martin Rao | Zendy; Davide Valentini | Zendy; Ernest Dodoo | Zendy; Alimuddin Zumla | Zendy; Markus Maeurer | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Anti-PD-1/PD-L1 therapy for infectious diseases: learning from the cancer paradigm

Author(s) -

Martin Rao,

Davide Valentini,

Ernest Dodoo,

Alimuddin Zumla,

Markus Maeurer

Publication year - 2017

Publication title -

international journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.278

H-Index - 89

eISSN - 1878-3511

pISSN - 1201-9712

DOI - 10.1016/j.ijid.2017.01.028

Subject(s) - cancer therapy , medicine , paradigm shift , cancer , intensive care medicine , philosophy , epistemology

Immune checkpoint pathways regulate optimal host immune responses against transformed cells, induce immunological memory, and limit tissue pathology. Conversely, aberrant immune checkpoint activity signifies a poor prognosis in cancer and infectious diseases. Host-directed therapy (HDT) via immune checkpoint blockade has revolutionized cancer treatment with therapeutic implications for chronic infections, thus laying the foundation for this review.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research